Maven Securities LTD Acquires New Holdings in CG Oncology, Inc. (NASDAQ:CGON)

Maven Securities LTD bought a new position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 140,000 shares of the company's stock, valued at approximately $4,015,000. Maven Securities LTD owned 0.18% of CG Oncology at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of CG Oncology in the fourth quarter worth $68,000. KLP Kapitalforvaltning AS acquired a new stake in shares of CG Oncology in the fourth quarter valued at about $100,000. Federated Hermes Inc. acquired a new position in shares of CG Oncology in the fourth quarter worth approximately $172,000. Meeder Asset Management Inc. bought a new stake in CG Oncology in the fourth quarter valued at approximately $189,000. Finally, NEOS Investment Management LLC increased its position in CG Oncology by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 8,329 shares of the company's stock valued at $239,000 after purchasing an additional 817 shares during the period. 26.56% of the stock is owned by institutional investors.

CG Oncology Trading Up 6.0%

NASDAQ CGON opened at $25.16 on Tuesday. The firm has a market capitalization of $1.92 billion, a P/E ratio of -17.72 and a beta of 1.08. The business has a fifty day simple moving average of $23.54 and a 200 day simple moving average of $28.39. CG Oncology, Inc. has a 12 month low of $14.80 and a 12 month high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). The company had revenue of $0.46 million for the quarter, compared to analysts' expectations of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. As a group, sell-side analysts predict that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CGON. HC Wainwright reiterated a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a research report on Monday, April 28th. JPMorgan Chase & Co. assumed coverage on CG Oncology in a research note on Friday, May 2nd. They issued an "overweight" rating and a $41.00 price target on the stock. Royal Bank of Canada increased their target price on shares of CG Oncology from $66.00 to $68.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 29th. Scotiabank initiated coverage on shares of CG Oncology in a research note on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 price target for the company. Finally, Morgan Stanley reissued an "overweight" rating and set a $55.00 price objective on shares of CG Oncology in a research report on Friday, March 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $57.70.

Insider Transactions at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $30.76, for a total transaction of $30,760.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 7.40% of the stock is owned by corporate insiders.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.